期刊
MOLECULAR DIAGNOSIS & THERAPY
卷 18, 期 2, 页码 213-227出版社
ADIS INT LTD
DOI: 10.1007/s40291-013-0069-9
关键词
-
资金
- Iceland Foods Ltd.
- Leonard Wolfson Experimental Neurology Centre
- Alzheimer's Research UK
- NIHR Queen Square Dementia BRU
- Swedish Research Council
The preclinical phase of Alzheimer's disease (AD) occurs years, possibly decades, before the onset of clinical symptoms. Being able to detect the very earliest stages of AD is critical to improving understanding of AD biology, and identifying individuals at greatest risk of developing clinical symptoms with a view to treating AD pathophysiology before irreversible neurodegeneration occurs. Studies of dominantly inherited AD families and longitudinal studies of sporadic AD have contributed to knowledge of the earliest AD biomarkers. Here we appraise this evidence before reviewing novel, particularly fluid, biomarkers that may provide insights into AD pathogenesis and relate these to existing hypothetical disease models.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据